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Dolly the sheep, the world’s first
mammal to be cloned from an
adult cell was put to sleep last
month. She was only six and a half
years old – barely 40 in human
terms. Already being treated for
arthritis, Dolly was found to be
suffering from a progressive lung
disease.
The premature death of Dolly
supports the view of some
scientists in Japan and the US
who maintain that all cloned
animals are born with health
problems. Harry Griffin,
spokesperson for the Roslin
Institute, near Edinburgh, where
Dolly was created, was cautious
on the significance of the ewe’s
death. ‘Sheep can live to 11 or 12
years,’ he said. ‘Lung infections
are common in older sheep,
particularly those housed inside. A
full postmortem is being
conducted and we will report any
significant findings.’ After the
postmortem examination, Dolly
will be stuffed and put on display
at the National Museum of
Scotland.
Dolly was born on July 5 1996,
from three mothers: one ewe to
provide the DNA, another to
provide the egg into which the
DNA was injected, and a third to
carry the resulting cloned embryo
to term. Dolly’s genetic mother
(the DNA was taken from an udder
cell) was six when she was
cloned. This may mean that the
real age of clones is their age
since birth, plus the age of the
genetic donor.
The revelation to the world of
Dolly’s existence, in 1997, was the
scientific sensation of the decade.
Scientific orthodoxy declared that
cloning mammals was impossible:
here was the proof. A frenzy of
speculation followed about what
cloning could achieve. But it is
now known that cloning is
difficult, expensive and
dangerous for the animals
involved. Claims of cloned
humans remain unproven.
Speculation about its potential
came quickly back to earth with
the announcement that Dolly had
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Goodbye Dolly: The creation of a cloned sheep caused a media sensation but her death demands a rethink of attitudes and presen-
tation of cloning and related stem cell research. (Picture: Science Photo Library.)
developed arthritis, which is
highly unusual in a sheep of her
age.
Speaking to reporters from
Dolly’s pen at the Roslin Institute,
the head of the original cloning
team, Ian Wilmut, put a brave face
on the sheep’s condition.
He said he was concerned and
called for more research into the
implications of cloning. But he
insisted that the technology was
crucial for medical science and
denied that he had opened a
Pandora’s box by showing that
mammals can be cloned. “This is
an inefficient procedure. We were
always aware that there was a risk
that we would find things like this.
We were very disappointed and
very concerned for the animals,”
he said.
“We will never know in the case
of Dolly whether the condition is
because she is cloned or whether
it is an unfortunate accident that
she developed arthritis. What’s
very important is that not only we
at the institute, but others who
produce cloned animals should
monitor their health throughout
their entire life span.”
Animal cloning is already known
as an unreliable and risky
procedure. It took 276
unsuccessful attempts before
Dolly was produced. Many cloned
animals which are carried to term
die shortly after birth and suffer
deformities. The University of
Missouri team implanted 3,000
embryos in 28 surrogate sows to
get just seven piglets.
“We must await the results of
the postmortem on Dolly in order
to assess whether her relatively
premature death was in any way
connected with the fact she was a
clone,” said Richard Gardener,
chairman of the Royal Society
working group on stem cell
research and therapeutic cloning.
“If there is a link, it will provide
further evidence of the dangers
inherent in reproductive cloning
and the irresponsibility of anybody
who is trying to extend such work
to humans.”
The drama surrounding the
creation of Dolly has had knock-
on effects for other areas of
research that may involve similar
techniques of nuclear transfer,
such as stem cell therapy. One of
the major obstacles to stem-cell
therapy with cells derived from
embryos or adult sources is that,
unless they came from a
compatible donor, they would be
treated as ‘foreign’ and rejected
by a patient’s immune system.
One way round this problem
would be to transfer a cell
nucleus from an individual into an
egg from which the nucleus has
been removed, after which the
newly created ‘embryo’ would be
used as a source of embryonic
stem cells for regenerative
therapy for that person. This
technique, called somatic cell
nuclear transfer, does, of course,
follow exactly the same steps as
would be required for human
reproductive cloning. Since there
would be no intention of placing
an egg treated in this way into a
uterus, the objectives of the
procedure would be completely
different. But researchers have
been caught in the ethical trap of
scrutiny of procedures that can
be used for entirely different ends
and many now believe the way
forward lies in distinguishing to
the public what the goals of
different research programmes
are.
It is clear then that, while stem
cell research is still at an early
stage of development and there
are many uncertainties, enough is
known already to suggest that the
medical benefits of a better
understanding of stem-cell
biology might be considerable.
But it cannot be advanced without
a source of human embryos.
While it has been suggested
that a better understanding of the
properties of embryonic stem
cells could be achieved by work in
the mouse and other animals, it is
already clear that there are many
differences between species in
the properties of these cells.
“It is not surprising that this
field has caused and still causes
considerable controversy. It is
particularly unfortunate that the
term ‘therapeutic cloning’ has
been applied in an uncritical and
blanket fashion. It is difficult to
dissociate it in people’s minds
from reproductive cloning, the
objective of which is totally
different,” says David Weatherall,
former head of the Institute of
Molecular Medicine, at Oxford
University.
Many countries are finding it
difficult to sort out these ethical
issues and to define a code of
practice for work in the stem cell
field. In the UK, after an extensive
study followed by a report from
the chief medical officer’s expert
group, and wide debate in
parliament, it is permissible to use
human embryonic stem cells
derived from ‘leftover’ embryos
not required by the genetic
parents for reproduction, or from
embryos created for research
purposes by in vitro fertilization,
or the nuclear transfer technique,
for specifically defined areas of
research. The legality of this
position is still questioned by
those who oppose any form of
research on embryos.
In Germany, research on human
embryonic stem cells was
prohibited, although it is allowed
in exceptional cases, provided it
is carried out on imported stem
cells derived before January 2000
from surplus embryos.
In the US, President Bush
announced in August 2001 that
federal funding for research in this
field could be used only for work
on 60 stem-cell lines that had
been derived from excess human
embryos before his
announcement. There is, however,
no federal law or policy
prohibiting the private sector from
creating stem cells by in vitro
fertilization or nuclear transfer.
Some of these issues are
described in a recent account of
stem cell research, based on the
assessment and work of a
committee chaired by cancer
researcher Bert Vogelstein, under
the auspices of the US National
Research Council. “The NRC
report reminds us how difficult it
is to develop an ethical
framework for a research field
that is so full of uncertainties and
potentials, and one in which the
technology skates close to
activities that are repugnant to
many people. But one thing this
increasingly bitter debate has
already made clear is that
scientists must be much more
precise, and less emotive, in the
language they use to describe
what they do,” says Weatherall.
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